Your browser doesn't support javascript.
loading
Beneficial Effects of Traditional Chinese Medicine Fuzheng Huayu on the Occurrence of Hepatocellular Carcinoma in Patients with Compensated Chronic Hepatitis B Cirrhosis Receiving Entecavir: A Multicenter Retrospective Cohort Study.
Fan, Haina; Lei, Shujuan; Zhao, Zhimin; Huang, Yan; Wang, Hui; Liu, Xudong; Li, Xiaodong; Xu, Min; Zhang, Wei; Sun, Kewei; Xing, Huichun; Mei, Yang; Huang, Jiaquan; Zhu, Chuanwu; Zhang, Kejun; Zong, Yali; Shen, Xizhong; Xie, Qing; Liu, Chenghai.
Afiliación
  • Fan H; Institute of Liver Diseases, Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Lei S; Institute of Liver Diseases, Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Zhao Z; Institute of Liver Diseases, Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Huang Y; Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Wang H; Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Liu X; Department of Infectious Diseases, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, Guangxi, China.
  • Li X; Institute of Liver Diseases, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, Hubei, China.
  • Xu M; Department of Infectious Diseases, Huaian Fourth People's Hospital, Huai'an, Jiangsu, China.
  • Zhang W; Institute of Liver Diseases, Shijiazhuang Fifth Hospital, Shijiazhuang, Hebei, China.
  • Sun K; Department of Liver Diseases, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China.
  • Xing H; Center of Hepatology, Capital Medical University Affiliated Beijing Ditan Hospital, Beijing, China.
  • Mei Y; Department of Hepatology, The Fifth People's Hospital of Anyang, Anyang, Henan, China.
  • Huang J; Department and Institute of Infectious Disease, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Zhu C; Department of Hepatology, The Fifth People's Hospital of Suzhou, Suzhou, Jiangsu, China.
  • Zhang K; Department of Gastroenterology, The First People's Hospital of Jingmen, Jingmen, Hubei, China.
  • Zong Y; Department of Integrated Traditional and Western Medicine, The Ninth Hospital of Nanchang, Nanchang, Jiangxi, China.
  • Shen X; Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Xie Q; Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Liu C; Institute of Liver Diseases, Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
J Clin Transl Hepatol ; 12(5): 505-515, 2024 May 28.
Article en En | MEDLINE | ID: mdl-38779515
ABSTRACT
Background and

Aims:

The application of antifibrotic drugs to treat patients with chronic liver diseases who are receiving antiviral therapies for hepatocellular carcinoma (HCC) has not been established. Here, we aimed to assess the impact of the Traditional Chinese Medicine Fuzheng Huayu (FZHY) on the occurrence of HCC in patients with hepatitis B virus-related compensated cirrhosis receiving the antiviral drug entecavir (ETV).

Methods:

A multicenter retrospective cohort study was performed. Compensated liver cirrhosis patients were divided into the ETV+FZHY group or the ETV group according to treatment. The cumulative incidence of HCC was analyzed using Kaplan-Meier and log-rank tests. Propensity score matching was used for confounding factors. Stratified analysis and Cox regression were used to determine the effects of FZHY on the occurrence of HCC and liver function decompensation.

Results:

Out of 910 chronic hepatitis B patients, 458 were in the ETV+FZHY group and 452 were in the ETV group. After propensity score matching, the 5-year cumulative incidence of HCC was 9.8% in the ETV+FZHY group and 21.8% in the ETV group (p<0.01). The adjusted hazard ratio for HCC was 0.216 (0.108, 0.432) when FZHY treatment was >36 months. Age, diabetes, alanine aminotransferase, γ-glutamyl transpeptidase, albumin, hepatitis B e-antigen, and fibrosis 4 score were associated with the occurrence of HCC. FZHY decreased the risk of HCC in patients aged >45 years with a hepatitis B virus DNA level of ≥2,000 IU/l.

Conclusion:

Adjunctive FZHY treatment reduced HCC occurrence in patients with hepatitis B virus cirrhosis who were treated with ETV, possibly due to the antifibrotic properties of FZHY.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Clin Transl Hepatol Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Clin Transl Hepatol Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos